Allianz Asset Management GmbH reduced its position in DENTSPLY SIRONA Inc (NASDAQ:XRAY) by 27.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 78,600 shares of the medical instruments supplier’s stock after selling 29,861 shares during the period. Allianz Asset Management GmbH’s holdings in DENTSPLY SIRONA were worth $5,174,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Jackson Square Partners LLC increased its stake in shares of DENTSPLY SIRONA by 8.8% in the 4th quarter. Jackson Square Partners LLC now owns 6,891,530 shares of the medical instruments supplier’s stock valued at $453,669,000 after buying an additional 556,624 shares during the period. Amalgamated Bank increased its stake in shares of DENTSPLY SIRONA by 9.7% in the 4th quarter. Amalgamated Bank now owns 28,439 shares of the medical instruments supplier’s stock valued at $1,872,000 after buying an additional 2,515 shares during the period. Champlain Investment Partners LLC increased its stake in shares of DENTSPLY SIRONA by 1.1% in the 4th quarter. Champlain Investment Partners LLC now owns 1,793,485 shares of the medical instruments supplier’s stock valued at $118,065,000 after buying an additional 20,010 shares during the period. Carillon Tower Advisers Inc. acquired a new stake in shares of DENTSPLY SIRONA in the 4th quarter valued at $4,717,000. Finally, Suntrust Banks Inc. increased its stake in shares of DENTSPLY SIRONA by 15.2% in the 4th quarter. Suntrust Banks Inc. now owns 7,727 shares of the medical instruments supplier’s stock valued at $507,000 after buying an additional 1,021 shares during the period. 96.80% of the stock is owned by institutional investors.
DENTSPLY SIRONA Inc (NASDAQ:XRAY) opened at $56.33 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.46 and a current ratio of 2.12. The firm has a market capitalization of $13,160.83, a PE ratio of -8.19, a price-to-earnings-growth ratio of 2.50 and a beta of 1.21. DENTSPLY SIRONA Inc has a twelve month low of $52.53 and a twelve month high of $68.98.
DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, March 1st. The medical instruments supplier reported $0.82 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.81 by $0.01. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.06 billion. DENTSPLY SIRONA had a positive return on equity of 8.35% and a negative net margin of 39.39%. The company’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.67 earnings per share. equities analysts predict that DENTSPLY SIRONA Inc will post 2.74 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, April 13th. Shareholders of record on Thursday, March 29th will be issued a dividend of $0.0875 per share. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $0.35 annualized dividend and a yield of 0.62%. DENTSPLY SIRONA’s dividend payout ratio is presently -5.09%.
Several research firms have recently issued reports on XRAY. HC Wainwright lowered DENTSPLY SIRONA from a “buy” rating to a “neutral” rating and set a $68.00 price target on the stock. in a research report on Thursday, November 30th. Zacks Investment Research lowered DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research report on Monday, January 8th. Stephens began coverage on DENTSPLY SIRONA in a research report on Tuesday, November 28th. They issued an “overweight” rating and a $75.00 price target on the stock. Credit Suisse Group lowered DENTSPLY SIRONA to a “hold” rating and set a $73.00 price target on the stock. in a research report on Friday, January 5th. Finally, BidaskClub lowered DENTSPLY SIRONA from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 2nd. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $67.43.
In other DENTSPLY SIRONA news, Director Eric Brandt sold 6,409 shares of DENTSPLY SIRONA stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $68.04, for a total transaction of $436,068.36. Following the transaction, the director now directly owns 12,073 shares in the company, valued at $821,446.92. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.99% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/03/17/allianz-asset-management-gmbh-lowers-stake-in-dentsply-sirona-inc-xray.html.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.
Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc (NASDAQ:XRAY).
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.